Week in review: Luxturna, Novartis, NIDEK

This week, Luxturna approaches EU approval, Novartis’ brolucizumab outperforms aflibercept in neovascular AMD trials and NIDEK unveils a “groundbreaking” gonioscopy device that performs 360-degree iridocorneal angle imaging in full color.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553